AzTrials
AzTrials

Full PRTNCT07724808

Rewiring Chronic Pain

A study testing Pain Reprocessing Therapy (PRT) and TAU in people with Full PRT and Partial PRT (Non Somtic), run by Ben-Gurion University of the Negev at 1 site in Israel.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study examines the effectiveness of a brief psychological intervention for chronic pain treatment, as well as the psychological and neurophysiological mechanisms associated with changes in pain intensity. Read more about this study

Who is it for?
Ages 20 to 70 years
What is being tested?
Pain Reprocessing Therapy (PRT) and TAU
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 siteIsrael
Study dates
1 Oct 2026to Dec 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 20-70 years
  • Chronic pain lasting over 3 months, including chronic pain conditions such as fibromyalgia and complex regional pain syndrome (CRPS)
  • Average pain intensity ≥4 on a 0-10 scale
  • Stable medication regimen for at least 4 weeks prior to treatment initiation
  • Hebrew language fluency
  • Provision of informed consent, including consent for video recordings

Who cannot join

  • Current participation in other pain-related psychotherapy
  • Pregnancy
  • Substance abuse, including deviations from prescribed medication use
  • Change in medication or dosage in the 4 weeks preceding treatment
  • Diagnosed active cancer
  • Dementia
Show all 10Show fewer
  • Severe depression (BDI-II score > 29)
  • Moderate cognitive impairment based on the Montreal Cognitive Assessment (MoCA)
  • Current or past diagnosis of schizophrenia, psychosis, bipolar disorder, multiple personality disorder, or dissociative identity disorder
  • Inability to undergo MRI as determined by MRI safety screening (e.g., claustrophobia, metal in body such as vascular clips, pacemakers, or certain cochlear implants)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Or Duek, Ph.D contact

+972-507606547

ord@bgu.ac.il

Israel1 site
  • Ben-Gurion University of the Negev

    Beersheba

    Lital Cohen-Blum, M.A., +972-522644388, cohelita@post.bgu.ac.il

Other trials in Israel

About this study

Official title: Rewiring Chronic Pain: Cognitive & Somatic Therapy Meets Neuroscience

This study examines the effectiveness of a brief psychological intervention for chronic pain treatment, as well as the psychological and neurophysiological mechanisms associated with changes in pain intensity.

Participants with chronic pain will be randomly assigned to one of three groups: two types of brief psychological interventions and a treatment-as-usual control group. Throughout the study, participants will attend a series of therapeutic sessions, complete questionnaires, undergo brain measurements (EEG and MRI), and participate in physiological monitoring using a smartwatch.

Read more

The study aims to investigate which cognitive and physiological changes occur during the intervention, and whether early markers can be identified that may predict improvement in pain following this type of treatment. In addition, differences between cognitive and somatic components of the intervention will be examined to better understand which elements contribute to clinical change, and to determine whether knowledge alone is sufficient or whether participants must undergo a bodily experience in order to produce changes in pain levels.

The goal of the study is to improve understanding of the mechanisms underlying chronic pain and responses to psychological treatments, and to contribute to the development of more personalized, effective treatments with minimal side effects in the future.

Read the detailed description

Chronic pain is estimated to affect 30% of adults and remains poorly managed by pharmacological approaches, which yield only modest pain reductions (~0.7-0.9 points on a 0-10 scale) and carry risks of sedation, misuse, and dependence. Short-term psychological interventions, particularly Pain Reprocessing Therapy (PRT), have shown large effects in randomized trials, yet the mechanisms driving their efficacy, and the specific contributions of cognitive versus somatic components, remain unclear.

Chronic pain has been consistently associated with structural and functional brain alterations in regions supporting sensory, affective, and interoceptive processing, including the ventromedial prefrontal cortex, anterior cingulate cortex, insula, and nucleus accumbens. Contemporary frameworks (e.g., the dynamic pain connectome) conceptualize chronic pain as a disorder of distributed network dysregulation rather than isolated regional dysfunction, motivating whole-brain functional connectivity, gray matter, and white matter analyses. At the electrophysiological level, slow-wave EEG activity, particularly theta (4-8 Hz) and alpha (8-12 Hz) power, has been linked to low-arousal states induced by hypnosis and mindfulness meditation, both of which produce clinical pain reduction. Animal evidence further links theta activity to neuroplasticity. On this basis, we hypothesize that arousal-state shifts indexed by EEG slow-wave activity and HRV coherence during PRT sessions will predict clinical improvement, and that pre-post MRI will reveal corresponding network and structural changes.

The proposed study is a single-blind, three-arm randomized controlled trial that will compare: (1) Full PRT integrating cognitive (psychoeducation) and somatic components (see full protocol at www.painreprocessingtherapy.com/wp-content/uploads/2024/10/PRT-Group-Protocol.pdf); (2) Partial PRT delivering only the cognitive component; and (3) Treatment as Usual (TAU). Both intervention arms will consist of eight 60-minute individual in-person sessions delivered twice weekly by trained providers, with real-time EEG monitoring during each session accessible to the provider to dynamically inform the therapeutic process. Randomization will be stratified by age and medication use, and participants will also be randomly assigned across providers to prevent provider-related confounding. A pilot phase (3-5 participants per intervention arm) will be conducted with EEG but without MRI to refine procedures.

Home practice will be standardized within each arm via a unified 8-10 minute audio recording: somatic tracking for the Full PRT arm, and an external-attention mindfulness exercise (sounds, smells, and visual imagery, deliberately avoiding bodily focus) for the Partial PRT arm, isolating the somatic component. Adherence will be self-reported. Assessment will occur at baseline, mid-treatment (abbreviated battery), post-treatment, and at follow-up (MRI up to 6 months; questionnaires up to 5 years). Twice-daily pain ratings and pre/post-session relaxation and valence ratings (0-10) will be collected throughout treatment.

Multimodal physiological and neural data will be collected as follows. MRI scans (pre- and post-treatment, ~40 min each) will include high-resolution T1-weighted anatomical imaging, resting-state fMRI, diffusion MRI, and 10 minutes of naturalistic audio-guided fMRI (5 min somatic tracking, 5 min neutral book chapter audio, both with eyes-closed via noise-cancelling headphones). EEG will be recorded during every intervention session using the g.tec Unicorn BCI Core-8 (8 channels, flexible montage). Continuous physiological monitoring via Garmin Vivosmart 5 wearables will capture heart rate variability (beat-to-beat intervals), sleep architecture, and daily activity levels for up to 6 weeks. Blood and saliva samples may also be collected.

Analyses will be conducted in Python. Clinical and physiological outcomes will be modeled using Bayesian mixed-effects general linear models to test whether markers of low-arousal states (EEG alpha/theta activity and HRV coherence) predict pain reduction, accounting for repeated measures and covariates. fMRI data will be preprocessed with fMRIPrep and analyzed using parcellation-based connectivity and Network-Based Statistic; structural MRI with FreeSurfer (gray matter volume); diffusion MRI with DIPY (fractional anisotropy); naturalistic fMRI with voxelwise encoding models; and EEG with MNE-Python. Exploratory multivariate prediction of clinical response will use machine learning classifiers.

Being tested
Pain Reprocessing Therapy (PRT), TAU
Keywords
chronic pain, resting-state fMRI, Pain Reprocessing Therapy (PRT), naturalistic neuroimaging, Network Based Statistic (NBS), functional connectivity, fMRI
Medical subject headings
Chronic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pain Reprocessing Therapy (PRT)Behavioural

    Also called PRT, Partial PRT

    In this full PRT, the participants will receive pain reprocessing therapy twice a week for four weeks (a total of 8 sessions). This treatment focuses on psychoeducation, cognitive restructuring and somatic elements.

    In the Partial PRT, participants will receive the same intervention, but without the somatic element.

  • TAUOther

    Participants in this arm will receive treatment as usual.

Study groups in NCT07724808
Study groupRoleWhat they receive
Treatment as UsualActive comparatorThis arm includes receiving the TAU treatment in chronic pain (oral medications and/or physical therapy).
Receives: Other: TAU
Pain Reprocessing Therapy (PRT)ExperimentalIn this condition, the participants will receive pain reprocessing therapy twice a week for four weeks (a total of 8 sessions). This treatment focuses on psychoeducation, cognitive restructuring and somatic elements.
Receives: Behavioral: Pain Reprocessing Therapy (PRT)
Partial PRTExperimentalIn this condition, participants will receive partial PRT, which includes psychoeducation and cognitive restructuring.
Receives: Behavioral: Pain Reprocessing Therapy (PRT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Average pain intensity in the first week post-treatment

    Participants will be prompted twice daily via the Labfront app, connected to their wearable, to respond to the following single item from the Brief Pain Inventory (BPI): "Please rate your pain by circling the one number that tells how much pain you have right now," rated on a 0-10 numeric scale (0 = "No pain"; 10 = "Pain as bad as you can imagine"). Prompts will be delivered during 6 weeks, where the primary outcome will be the mean of all valid responses collected during the first week post-treatment.

    Measured: Twice a day for 6 weeks

Secondary outcomes (13)
  1. Pain severity: pre- to post-treatment score difference

    Score of pain severity from Brief Pain Inventory- short form (average of items 3-6)

    Measured: 4 weeks of treatment

  2. Pain interference: pre- to post-treatment score difference

    Score of pain interference from Brief Pain Inventory- short form (average of items 9A-9G)

    Measured: 4 weeks of treatment

  3. Pain levels (0-10) at up to 6 months follow-up

    Participants will complete the Brief Pain Inventory (BPI) questionnaire, which includes the item: "Please rate your pain by circling the one number that best describes your pain on average (in the last week)," rated on a 0-10 numeric scale (0 = "No pain"; 10 = "Pain as bad as you can imagine"). The response to this item will serve as a secondary outcome measure of average pain intensity over the preceding week, assessed at up to 6-month follow-up.

    Measured: Up to 6 months post-treatment

  4. Anxiety levels: pre- to post-treatment difference

    Score of Generalized Anxiety Disorder questionnaire (GAD-7)

    Measured: 4 weeks of treatment

  5. Depression levels: pre- to post-treatment difference

    Score of the questionnaire Beck depression inventory || (BDI-II)

    Measured: 4 weeks of treatment

  6. Sleep quality- wearables

    Assessing sleep quality using smartwatches

    Measured: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).

  7. Sleep quality: pre- to post-treatment questionnaire score difference

    Difference in scores of Insomnia Severity Index (ISI)

    Measured: 4 weeks of treatment

  8. Self-rated health: pre- to post-treatment questionnaire score difference

    Difference in score of the Short Form Survey (SF-12) questionnaire

    Measured: 4 weeks of treatment

  9. Pain catastrophizing: pre- to post-treatment score difference

    Difference in score of Pain Catastrophizing Scale (PCL) questionnaire

    Measured: 4 weeks of treatment

  10. Emotional regulation: pre- to post-treatment score difference

    Difference in score of the Emotional Regulation Questionnaire (ERQ)

    Measured: 4 weeks of treatment

  11. Causal attribution: change form pre- to post-treatment

    Potential shift from words that are associated with body structure and positions to ones that are associated with mind, emotions and cognition.

    Measured: 4 weeks of treatment

  12. Heart Rate Variability (HRV)- wearables

    Assessing HRV using smartwatches

    Measured: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).

  13. Movement- wearables

    Assessing movement, including number of steps per day, using smartwatches

    Measured: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completionDec 2029 (estimated)
  4. Study completionDec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07724808
Sponsor's protocol ID
SOR-26-0181
Status last verified
Jul 2026
First submitted
28 Jun 2026
Last updated
24 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: We will de-identify the information and allow access to all data elements (except identifying data)

Publications

  • Ashar YK, Gordon A, Schubiner H, Uipi C, Knight K, Anderson Z, Carlisle J, Polisky L, Geuter S, Flood TF, Kragel PA, Dimidjian S, Lumley MA, Wager TD. Effect of Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Jan 1;79(1):13-23. doi: 10.1001/jamapsychiatry.2021.2669.

    PubMed 34586357

Questions about this trial

What is this clinical trial studying?

A study testing Pain Reprocessing Therapy (PRT) and TAU in people with Full PRT and Partial PRT (Non Somtic), run by Ben-Gurion University of the Negev at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 24 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Or Duek, Ph.D (+972-507606547, ord@bgu.ac.il), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Average pain intensity in the first week post-treatment (time frame: Twice a day for 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07724808, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in